VIVUS, Inc. (NASDAQ:VVUS) announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is -3.93%. On last trading day company shares ended up $4.64. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -13.20%.
Shares of Arena Pharmaceuticals Inc (NASDAQ:ARNA) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 50,611,732 shares, a drop of 4.3% from the April 15th total of 52,859,238 shares,AmericanBankingNews.com reports. Currently, 23.3% of the shares of the stock are sold short. Based on an average daily volume of 4,298,044 shares, the short-interest ratio is presently 11.8 days. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -0.96% in last trading session and ended the day on $6.19. Gross Margin is 93.70% and its return on assets is -8.10%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -11.70%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) said local Chinese authorities visited one of its facilities this week, the latest in a series of moves that analysts say mark Beijing’s efforts to maintain government pressure on the pharmaceutical industry. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) shares moved down -0.27% in last trading session and was closed at $37.42 , while trading in range of $37.37 – $37.53.
MannKind Corporation (NASDAQ:MNKD)’s stock was upgraded to Neutral from Underweight at Piper Jaffray on May 14 citing management’s confidence in Afrezza approval and partnership opportunities. Piper raised price target to $6.50 from $2.0 MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $7.77. Company weekly volatility is calculated as 5.49% and price to cash ratio as 84.35. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 10.68%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -0.94%. On last trading day company shares ended up $6.30. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -13.98%.
Leave a Reply